Abstract:The mutation of tumor suppressor p53 gene is common in malignant tumor. p53 antibodies are products of immunoresponse against abnormal p53 protein. It has been found that p53 antibodies are of importance in tumor's diagnosis, prognosis and relapse monitoring. However, current method for detecting p53 antibodies, i.e. enzyme-linked immunosorbent assay (ELISA), requires a long time with multiple steps, and the assay is only semi-quantitative. In this work, a protocol for quantitative detection of p53 antibodies in human serum using immunomagnetic electrochemiluminescence (IM-ECL) was devoloped. The immunoassay format consisted of a three antibody sandwich in which a biotinylated capture antibody, was banded with the commercial p53 protein. A detector antibody was added to bind the p53 protein at another site. Then, secondary antibody, labeled with ruthenium(II) tris-bipyridal, was added and, when bound to the bead immunocompiex, generated light in the presence of an excess of tripropylamine. The light was detected and measured by the analyzer made by us. Our experimental results indicate that the sensitivity of this assay was 10 pg of p53 antibodies per ml of reference serum (normal human serum). A stable calibration curve with a wide dynamic range was established. The calibration curve was linear from 0.01 to 1000 ng/ml, thus, making quantitation possible. An immunologic prozone effect was observed above 1000 ng p53 antibodies per milliliter of serum. Serum samples from lung and nasopharyngeal carcinoma patients were tested using the IM-ECL assay. The positive rate of p53 antibodies were 28.6% in lung carcinoma and 8.33% in nasopharyngeal carcinoma, respectively. p53 antibody concentration in the carcerous human sera were quantified from the calibration curve. In the case of lung carcinoma, a trend was found that a higher p53 antibody concentration in the serum was likely linked to a higher stage of the cancer. This trend was not found in nasopharyngeal carcinoma. The assay uses only 50 μl of sample per test and requires a 30-min incubation period in addition to a 50 s acquisition time. This assay has several advantages over the commonly used ELISA method in terms of sensitivity, linear range, and assay time. Results of the study suggest that IM-ECL is a feasible method for rapid and sensitive detection of p53 antibodies in human serum.

Secreted recombinant P53 protein from Pichia pastoris is a useful antigen for detection of serum p53: autoantibody in patients with advanced colorectal adenocarcinoma

Establishment of cloned homogeneous immunoassay for detection of P53 protein in serum and stool samples from patients with gastric carcinoma

The Potential for Serum P53 to Predict the Response to Chemotherapy of Patients with Gastric Cancer

Rapid and sensitive immunomagnetic-electrochemiluminescent detection of p53 antibodies in human serum.

Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival

Clinical Significance of P53 Expression in Colorectal Cancer Patients

The Expression and Importance of P53 Protein in Colorectal Carcinoma

Potential Diagnostic Value of Serum P53 Antibody for Detecting Colorectal Cancer: A Meta-Analysis.

The value of serum p53 antibody as a biomarker in oral and pharyngeal squamous cell carcinoma

Value of Serum P53 Antibody As a Tumor Marker Surveillance of Colorectal Cancer Within Follow-Up after Curative Resection

Comparison between p53 staining in tissue sections and p53 proteins levels measured by an ELISA technique

Serum P53 Protein and Anti-P53 Antibodies Are Associated with Increased Cancer Risk: a Case–control Study of 569 Patients and 879 Healthy Controls

Surface enhanced Raman spectroscopy based immunosensor for ultrasensitive and selective detection of wild type p53 and mutant p53R175H

Detection of serum anti-p53 antibodies from patients with ovarian cancer in China: correlation to clinical parameters.

Expression and Immunogenicity Analysis of p53 Protein Fused with a New Cell-Penetrating Peptide

[Correlation Between Serum P53 Antibody and Chemosensitivity in Patient with Esophageal Cancer].

p53 expression in colorectal adenomas.

Clinical significance of the post/preoperative anti-p53 antibody ratio in predicting the prognosis of patients with colorectal cancer after curative surgery and its usefulness in combination with carcinoembryonic antigen

P 53 Fusion Protein Expression in Prokaryote and Preparation of Monoclonal Antibody to P 53

P<sup>53</sup> fusion protein expression in prokaryote and preparation of monoclonal antibody to P<sup>53</sup>

[Detection of P53 Gene Change and Serum Antibody Level in Phase II Clinical Trial of Ad P53 Gene Therapy].